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The anti-cholesterolaemic effect 
of a consortium of probiotics: An 
acute study in C57BL/6J mice
D. R. Michael1, T. S. Davies1, J. W. E. Moss2, D. Lama Calvente1, D. P. Ramji2,  
J. R. Marchesi  2,3, A. Pechlivanis5, S. F. Plummer1 & T. R. Hughes4
Hypercholesterolaemia is a major risk factor for cardiovascular disease and it has been found that 
some probiotic bacteria possess cholesterol-lowering capabilities. In this study, the ability of the Lab4 
probiotic consortium to hydrolyse bile salts, assimilate cholesterol and regulate cholesterol transport 
by polarised Caco-2 enterocytes was demonstrated. Furthermore, in wild-type C57BL/6J mice fed a high 
fat diet, 2-weeks supplementation with Lab4 probiotic consortium plus Lactobacillus plantarum CUL66 
resulted in significant reductions in plasma total cholesterol levels and suppression of diet-induced 
weight gain. No changes in plasma levels of very low-density lipoprotein/low-density lipoprotein, 
high-density lipoprotein, triglycerides, cytokines or bile acids were observed. Increased amounts of 
total and unconjugated bile acids in the faeces of the probiotic-fed mice, together with modulation of 
hepatic small heterodimer partner and cholesterol-7α-hydroxylase mRNA expression, implicates bile 
salt hydrolase activity as a potential mechanism of action. In summary, this study demonstrates the 
cholesterol-lowering efficacy of short-term feeding of the Lab4 probiotic consortium plus L. plantarum 
CUL66 in wild-type mice and supports further assessment in human trials.
Cardiovascular disease (CVD) is the cause of death in one in three people in the United Kingdom1 and is the 
leading cause of global mortality2. Hypercholesterolaemia is a major risk factor for the disease and statins are 
widely used to normalise elevated circulating cholesterol levels and can reduce CVD-related events by approx-
imately 25%3–7 and are often associated with adverse side effects8. Primary and secondary care of CVD imparts 
a heavy economic burden on society1. Management of modifiable lifestyle risk factors, such as diet, body weight 
and physical activity, represent preventative measures and are advocated by healthcare providers7, 9. However, the 
high mortality rates associated with CVD suggest these measures are not sufficiently effective and further options 
are required10–12.
Probiotics are defined as “live microorganisms that, when administered in adequate amounts, confer a health 
benefit on the host”13, 14 and there is growing evidence that some probiotic organisms possess a cholesterol lower-
ing capability and could be considered as a potential supplemental tool in combatting CVD and associated con-
ditions15. The cholesterol-lowering efficacy of a diversity of microbial species and strains has been observed16–21. 
There are multiple mechanisms by which these effects are thought to occur including the assimilation of cho-
lesterol22 and/or the deconjugation of bile salts by bile salt hydrolase (BSH) positive probiotic bacteria that put 
increased demand on de novo bile synthesis (from circulating cholesterol) to replace that which is lost in faeces23, 24. 
Probiotic bacteria have also been shown to modulate key intestinal cholesterol transport pathways by regulating 
gene expression patterns of Niemann-Pick C1-like 1 (NPC1L1), ATP-binding cassette sub-family G member 
(ABCG)-5, ABCG-8 or ATP-binding cassette transporter-1 (ABCA-1) in intestinal epithelial cells25–29.
L. plantarum CUL66 (NCIMB 30280) has been found to have a cholesterol-lowering capability29 and the 
effects of the Lab4 consortium of probiotics (Lab4, composed of Lactobacillus acidophilus CUL21 (NCIMB 
30156) and CUL60 (NCIMB 30157), Bifidobacterium bifidum CUL20 (NCIMB 30153) and Bifidobacterium 
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animalis subsp. lactis CUL34 (NCIMB 30172) during other conditions are documented30–33. In the present study, 
assessment of the cholesterol lowering capabilities of Lab4 was made in vitro prior to its inclusion, in combination 
with L. plantarum CUL66, in a short-term feeding study with C57BL/6J mice on a high fat diet.
Results
Evidence for cholesterol lowering ability by Lab4 in vitro. BSH activity in Lab4 was indicated by the 
formation of a white precipitate and agar-clouding in the presence of 0.5% TDCA (Fig. 1a; right-sided panels) 
that was absent on control agar (Fig. 1a; left-sided panels). Growing cultures of Lab4 removed 26.54% (p = 0.076) 
of cholesterol from MRS broth (Fig. 1b) equating to 4.84 ± 5.27 mg of cholesterol per gram of dry weight bacteria.
As seen in Fig. 2a, when incubated with 21-day polarised Caco-2 cells and cholesterol (70 µg/ml), live cultures 
of Lab4 reduced NPC1L1 and ABCA-1 gene expression by 33% (p = 0.00002) and 37% (p = 0.001) respectively 
and increased 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene expression by 35% (p = 0.012) when 
compared to cells treated with cholesterol alone (Control). No significant changes in ABCG-5 or ABCG-8 gene 
expression were observed. The viability of both Caco-2 cells and Lab4 was maintained throughout the experiment 
(Supplementary Figure S1).
No substantial changes in the uptake of extracellular radiolabelled cholesterol were observed in response 
to Lab4 (Fig. 2b) despite reduced expression of NPC1L1 (Fig. 2a) and the ability of Lab4 to assimilate 
cholesterol (Fig. 1b). Reduced gene expression of ABCA-1 (Fig. 2a) was also observed in response to Lab4 
Figure 1. BSH activity and cholesterol assimilation by Lab4. (a) De Man, Rogosa and Sharpe (MRS) agar plates 
(control, top and bottom left-sided panels) or MRS agar plates containing 0.05% taurodeoxycholic acid (TDCA, 
top and bottom right-sided panels) that were inoculated with Lab4 on filter discs (top panels) or as bacterial 
streaks (bottom panels, n = 1) for 48 hours under anaerobic conditions. (b) Cholesterol concentration in MRS 
broth containing 0.3% (w/v) ox-bile and 200 µg/ml cholesterol (control) or in MRS broth containing 0.3% (w/v) 
ox-bile and 200 µg/ml cholesterol that were inoculated with Lab4 for 18 hours under anaerobic conditions. 
The data are presented as a representative image from 3 identical experiments (unless stated, Fig. 1a) or the 
mean ± SD from three independent experiments (Fig. 1b). Statistical analysis was performed using Student’s t-
test and values of p are stated where appropriate.
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suggesting a possible impact on cholesterol transport. As seen in Fig. 2c, the apical application of viable 
Lab4 cultures to Caco-2 cells housed in a dual compartment trans-well system significantly reduced the 
basolateral efflux of intracellular radiolabelled cholesterol compared to the control (35%, p = 0.004). The 
magnitude of this reduction is in line with the 37% reduction in ABCA-1 gene expression (Fig. 2a). No 
changes in the efflux of intracellular radiolabelled cholesterol into the extracellular apical compartment 
were observed (Fig. 2d).
Short-term feeding of mice with Lab4 and L. plantarum CUL66 reduces plasma total choles-
terol (TC) and diet-induced weight gain but has no effect on plasma very low-density lipo-
protein (VLDL)/low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides 
(TG) or cytokines. As expected, mice in the high fat diet (HFD) group presented elevated plasma levels 
of TC (2.89 mM vs 3.64 mM, p = 0.001), VLDL/LDL (0.41 mM vs 0.79 mM, p = 0.000003) and HDL (1.73 mM 
vs 2.04 mM, p = 0.054) compared to baseline (BL) values although TG levels remained unchanged (Table 1). 
Between group comparison showed that plasma TC was significantly reduced by 14% (3.64 mM vs 3.15 mM, 
p = 0.029) in the high fat diet plus probiotic (HFD + P) group compared to the HFD group to a level similar to BL 
levels. Plasma cytokines were not changed in response to the high fat diet (BL vs HFD) or probiotic feeding (HFD 
Figure 2. The effect of Lab4 on cholesterol homeostasis in Caco-2 enterocytes. (a) Gene transcript levels of 
NPC1L1, ABCG-5, ABCG-8, ABCA-1 and HMGCR in Caco-2 cells that were treated with 70 µg/ml cholesterol 
(Control) or cholesterol (70 µg/ml) and Lab4 (1 × 108 cfu/ml) for 6 hours. Gene transcript levels were calculated 
using the comparative cycle threshold (Ct) method and normalised to β-actin levels with the control given 
an arbitrary value of 1.0. (b) Cholesterol uptake by untreated (control) Caco-2 cells or those incubated with 
Lab4 (1 × 108 cfu/ml) for 5 hours prior to the addition of radiolabelled cholesterol for an additional hour. 
Intracellular radioactivity (disintegrations per minute) was normalised to total protein content and presented 
as a percentage of the control that has been arbitrarily assigned as 100%. Efflux of intracellular radiolabelled 
cholesterol to apolipoprotein-AI (Apo-AI, 10 μg/ml) in the basolateral compartment (c) or TDCA micelles 
(1 nM) in the apical compartment (d) by untreated (control) Caco-2 cells or those treated with Lab4 (1 × 108 
cfu/ml) for 6 hours. The percentage of intracellular cholesterol effluxed from the cells was determined by 
dividing the radioactivity of the apical media or basolateral media by the combined radioactivity in the 
apical media, basolateral media and cell fraction. The data are presented as the mean ± SD from at least three 
independent experiments. Statistical analysis was performed using Student’s t-test where *p < 0.05, **p < 0.01 
and ***p < 0.001.
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vs HFD + P) although significantly elevated levels of keratinocyte chemoattractant/growth-regulated oncogene 
were observed in the HFD + P group compared to BL levels (63.19 pg/ml vs 89.62 pg/ml, 42%, p = 0.045). Mice 
in the HFD + P group showed significantly less weight gain after 14 days feeding compared to the HFD group 
(10.92% vs 15.33% respectively, p = 0.025, Fig. 3). No residual food was found during daily cage checks.
Short-term feeding with Lab4 plus L. plantarum CUL66 has no effect on plasma bile acids, 
but increases faecal bile acid excretion. Analysis of bile acids did not identify any differences between 
groups in the levels present in the plasma (Fig. 4a and b). In contrast, mice fed HFD and HFD + P have differ-
ent faecal bile acid profiles to the BL group (Fig. 4c and d) and the faecal bile acid profile of HFD + P fed mice 
is more variable than those fed HFD alone (Fig. 4c). Plasma and faecal bile acid profiles (as relative intensities 
from UPLC-MS) are shown in Supplementary Table S1 and Supplementary Figure S2. Unlike plasma levels that 
remained unchanged, total and unconjugated bile acid levels were significantly increased in the faeces of both 
groups during the study compared to BL and significantly higher levels of total (34% increase, p = 0.047) and 
unconjugated bile acids (33% increase, p = 0.047) were present in the faeces of HFD + P mice compared to the 
HFD group (Table 2). Increased relative levels of ursodeoxycholic acid (46% increase, p = 0.003), hyodeoxycholic 
acid (96% increase, p = 0.028), taurochenodeoxycholic acid (180% increase, p = 0.026) and a trend towards an 
increase in deoxycholic/chenodeoxycholic acid (30%, p = 0.052) were observed in the faeces of HFD + P mice 
compared to the HFD group (Table 2).
BL HFD HFD + P
Plasma Lipids (mM)
Total cholesterol 2.89 ± 0.09 3.64 ± 0.33** 3.15 ± 0.38#
Very low-density lipoprotein/low-
density lipoprotein 0.41 ± 0.10 0.79 ± 0.07*** 0.69 ± 0.09***
High-density lipoprotein 1.73 ± 0.14 2.04 ± 0.23p=0.054 1.79 ± 0.26
Triglycerides 0.76 ± 0.14 0.80 ± 0.15 0.71 ± 0.12
Plasma Cytokines (pg/ml)
Interferon-γ 0.59 ± 0.26 0.61 ± 0.39 0.97 ± 0.41
Interleukin-10 14.23 ± 4.26 12.83 ± 2.56 15.18 ± 3.83
Interleukin-12p70 51.11 ± 54.01 30.05 ± 32.06 19.80 ± 12.17
Interleukin-1β 0.84 ± 0.59 0.74 ± 0.49 0.60 ± 0.24
Interleukin-2 3.24 ± 1.46 2.84 ± 1.41 2.14 ± 0.60
Interleukin-4 0.72 ± 0.57 0.43 ± 0.37 0.37 ± 0.13
Interleukin-5 2.95 ± 0.64 3.14 ± 1.20 3.18 ± 0.34
Interleukin-6 6.37 ± 2.13 10.22 ± 8.47 10.39 ± 3.80
Keratinocyte chemoattractant/growth-
regulated oncogene 63.19 ± 15.62 75.36 ± 14.15 89.62 ± 21.26*
Tumor Necrosis Factor-α 10.7 1 ± 1.27 11.47 ± 2.59 15.34 ± 5.16
Table 1. Plasma lipid and cytokine concentrations. Data represent the means ± standard deviation of 6 mice 
per group. Values of p were determined using one-way ANOVA with Tukey’s (equal variance) or Dunnett’s T3 
(unequal variance) post-hoc analysis where ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 versus the BL group; #p < 0.05 
versus the HFD group. Values of p compared to the BL group are stated where appropriate.
Figure 3. Effect of probiotics on body weight. Body weights of mice in the HFD and HFD + P groups were 
recorded throughout the intervention period at the indicated time points and the percentage change in body 
weight since day 0 was calculated for each mouse. Data is presented as the mean ± SD for 6 mice in each group. 
Statistical analysis was performed using Student’s t-test where *p < 0.05.
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Short-term feeding with Lab4 plus L. plantarum CUL66 modulates the expression of genes 
associated with hepatic bile metabolism, but has no effect on those associated with cholesterol 
metabolism/transport in the duodenum, colon or liver. Significantly reduced mRNA levels of small 
heterodimer partner (SHP, 42%, p = 0.010) and significantly elevated mRNA levels of cholesterol-7α-hydroxylase 
(CYP7A1, 84%, p = 0.047) were observed in the livers of the HFD + P mice when compared to those fed HFD 
alone (Table 3). A trend towards an increase in hepatic ABCG-8 mRNA (23%, p = 0.067) was observed in 
HFD + P when compared to those fed HFD alone (Table 3). No significant differences between groups in the 
expression of farnesoid X receptor (FXR), NPC1L1, ABCG-5, ABCG-8, ABCA-1 and HMGCR were observed in 
duodenal, colonic or liver tissues (Table 3). Fibroblast growth factor 15 (FGF15) mRNA could not be detected in 
the duodenum or colon (Table 3).
Discussion
In this short-term feeding study, daily probiotic supplementation resulted in lower plasma cholesterol levels and 
suppression of diet-induced weight gain in mice fed a high fat diet. High circulating levels of TC and obesity are 
associated with increased risk of CVD and reductions in cholesterol levels and body weight can have a beneficial 
impact on this disease2. The cholesterol-lowering and anti-obesity effects observed for Lab4 plus L. plantarum 
CUL66 support the findings of longer term feeding studies in C57BL/6J mice with other probiotics34–40 and fur-
ther implicate probiotic supplementation as a potential strategy for the prevention of metabolic disease.
The deconjugation of bile acids by bacterial BSH activity is considered a key probiotic cholesterol-lowering 
mechanism22, 26, 41–44 and can increase faecal bile acid excretion in C57BL/6J mice35, 45 by repressing the entero-
hepatic FXR-FGF15 axis45 and increasing hepatic bile acid synthesis35, 45. In this study, we propose that reduced 
plasma cholesterol levels (Table 1) are the consequence of increased bile synthesis de novo by the host in response 
to probiotic-mediated bile acid deconjugation in the intestines. This view is supported by numerous obseva-
tions: firstly, the ability of Lab4 (Fig. 1a) and L. plantarum CUL6629 to deconjugate bile acids in vitro. Secondly, 
increased levels of total and unconjugated bile acids in the faeces of probiotic fed mice (Table 2). Thirdly, a 
reduction in hepatic gene expression of SHP; a transcriptional repressor of CYP7A1; the rate limiting enzyme 
in the synthesis of bile salts from cholesterol46. Finally, the concomitant increase in hepatic mRNA CYP7A1 
levels (Table 3) that has consistently shown direct correlation with increased hepatic CYP7A1 protein levels in 
Figure 4. Principle component analysis (PCA) and heatmap analysis of plasma and faecal bile acid profiles. 
PCA score plots of bile acid signatures from the (a) plasma or (c) faeces of BL, HFD and HFD + P mice. 
Heatmaps of the bile acid relative intensity from (b) plasma or (d) faeces of each mouse.
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numerous other studies47–49. It should also be noted that these changes were not accompanied with changes in 
plasma bile acids (Table 2) or intestinal FXR mRNA expression (Table 3) in accordance with observations made 
elsewhere45, although gene expression levels in the ileum; the key site of FXR-FGF15 activation50, 51, were not 
assessed in our study due to non-availability of tissue.
Probiotics have also been shown to lower cholesterol levels by regulating cholesterol transport and metabo-
lism25–27, 29 and both Lab4 (Fig. 2a) and L. plantarum CUL6629 have been shown to inhibit the expression of the 
cholesterol uptake transporter NPC1L1 in human intestinal epithelial cells. For L. plantarum CUL66, decreased 
PLASMA FAECES
HFD HFD + P HFD HFD + P
Total bile acids 1.39 ± 0.56 1.07 ± 1.20 1.72 ± 0.34* 2.30 ± 0.49***#
Conjugated bile acids 1.56 ± 1.13 0.90 ± 0.57 2.07 ± 1.21 3.62 ± 2.96*
Unconjugated bile acids 1.35 ± 0.48 1.11 ± 1.46 1.71 ± 0.33* 2.27 ± 0.46***#
Individual bile acids
Ursocholanic Acid ND ND 1.16 ± 0.44 1.32 ± 0.47
3-Ketocholanic Acid ND ND 1.12 ± 0.51 1.39 ± 0.70
Lithocholic acid ND ND 1.11 ± 0.33 1.25 ± 0.46
Allolithocholic Acid ND ND 1.38 ± 0.65 1.98 ± 1.08
Isolithocholic Acid ND ND 1.11 ± 0.55 1.22 ± 0.55
3,6/12-Diketocholanic Acid ND ND 0.94 ± 0.80 1.58 ± 1.04
3α-Hydroxy-12 Ketolithocholic Acid ND ND 1.74 ± 0.61 2.47 ± 0.87*
Deoxycholic Acid/Chenodeoxycholic ND ND 1.29 ± 0.17 1.68 ± 0.28*p=0.052
5β-Cholanic Acid-3β, 12α-diol ND ND 0.94 ± 0.23 1.17 ± 0.37
Murocholic Acid ND ND 3.07 ± 1.77** 4.83 ± 2.54***
Ursodeoxycholic acid ND ND 1.58 ± 0.11* 2.31 ± 0.36**##
Hyodeoxycholic acid ND ND 2.26 ± 0.91** 4.42 ± 1.91***#
12-Dehydrocholic Acid 0.59 ± 0.27 0.59 ± 0.78 2.41 ± 1.09* 2.58 ± 1.29*
ω-Muricholic Acid 0.93 ± 0.32 0.59 ± 0.77 1.87 ± 0.39** 2.22 ± 0.46**
α/β-Muricholic acid 2.41 ± 0.99 1.94 ± 2.49 2.98 ± 1.19*** 4.28 ± 1.29***
Hyocholic acid ND ND 1.20 ± 0.38 1.67 ± 0.43
Cholic acid 1.49 ± 0.63 1.35 ± 1.82 17.00 ± 16.70 18.82 ± 15.33***
Taurochenodeoxycholic Acid 9.18 ± 9.09* 4.36 ± 3.04 2.99 ± 1.32* 8.40 ± 5.75***#
Taurodeoxycholic Acid 1.08 ± 0.88 0.86 ± 0.53 6.12 ± 4.21** 13.75 ± 13.81***
Tauro-ursodeoxycholic Acid 1.50 ± 0.26 1.16 ± 0.66 3.88 ± 2.51* 6.25 ± 4.50**
Taurohyodeoxycholic Acid ND ND 2.73 ± 1.50* 7.25 ± 5.46**
Taurocholic Acid 0.88 ± 0.82 0.50 ± 0.43 0.60 ± 0.22 1.29 ± 1.08
Tauro-ω,α,β Muricholic Acid 1.99 ± 1.27 1.04 ± 0.62 2.70 ± 1.76 3.64 ± 2.64**
Table 2. Ratio of plasma and faecal bile acid content in relation to BL group. Data represent the means ± SD 
of 4 (plasma) or 6 (faeces) mice per group. Values of p were determined using one-way ANOVA with Tukey’s 
(equal variance) or Dunnett’s T3 (unequal variance) post-hoc analysis where ∗p < 0.05, ∗∗p < 0.01, and 
∗∗∗p < 0.001 versus the BL group; #p < 0.05, ##p < 0.01, and ###p < 0.001 versus the HFD group. Values of p 
compared to the HFD group are stated where appropriate. ND, not detected.
DUODENUM COLON LIVER
FXR 1.26 ± 1.20 1.78 ± 1.09 1.27 ± 0.25
FGF15 ND ND NT
SHP NT NT 0.58 ± 0.18*
CYP7A1 NT NT 1.84 ± 0.69*
HMGCR 0.87 ± 0.72 2.16 ± 1.56 0.95 ± 0.19
NPC1L1 0.91 ± 0.56 0.89 ± 0.61 1.37 ± 0.35
ABCG5 1.14 ± 0.31 0.92 ± 0.68 1.03 ± 0.17
ABCG8 1.00 ± 1.20 0.78 ± 0.47 1.23 ± 0.20p=0.067
ABCA1 0.60 ± 0.66 0.75 ± 0.55 0.96 ± 0.31
Table 3. Ratio of expression of key genes involved in bile acid and cholesterol metabolism in the HFD+P group 
in relation to the HFD group. Data represent the means ± SD of 6 mice per group values of p were determined 
using Student’s t-test where ∗p < 0.05. Values of p compared to the HFD group are stated where appropriate. NT, 
not tested; ND, not detected.
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expression was associated with decreased extracellular cholesterol uptake together with increased expression of 
apical cholesterol efflux proteins ABCG-5 and ABCG-829, but was not associated with any changes in cholesterol 
export into the apical compartment29. Lab4 and L. plantarum CUL66 have been shown to reduce the expression 
of the cholesterol efflux transporter ABCA-1 which may be linked to the observed reductions of ApoAI-mediated 
basolateral cholesterol efflux (Fig. 2c)29. Interestingly, transcript levels of the de novo cholesterol synthesis enzyme 
HMGCR were increased and this change could represent a compensatory mechanism used to maintain cellu-
lar cholesterol levels29, 52–54. The changes in gene expression that had been observed in cultured human Caco-2 
enterocytes in vitro may represent a species-specific effect as similar changes were not detected in the duodenal or 
colonic tissue analysed on completion of the murine feeding study (Table 3).
Assimilation of cholesterol is thought to be another mechanism by which probiotic bacteria can influence 
plasma cholesterol levels55 although the impact of cholesterol assimilation by Lab4 (Fig. 1b) and L. plantarum29 
seen in vitro could not be assessed in vivo due a limited availability of faecal sample. Likewise, it was not possible 
to assess the impact of other potential probiotic cholesterol-lowering mechanisms such as the conversion of cho-
lesterol to coprostanol, short chain fatty acid production55 and the assimilation of bile acids56, 57. Probiotics have 
also been shown to reduce blood TG levels37, 38 or impart anti-inflammatory effects34, 40 in HFD fed C57BL/6J 
mice but these responses were not seen in our study (Table 1) possibly as a result of the short intervention period.
In summary, this preliminary 2 week study in mice on a high fat diet demonstrated the cholesterol-lowering 
capability of a combination of Lab4 and L. plantarum CUL66 probiotic bacteria. The probiotic group presented 
lower plasma TC levels and reduced weight gain together with changes in faecal bile acid content which impli-
cates the deconjugation of bile salts as a potential mechanism of action. These findings provide a meaningful basis 
for the design of follow-up studies to assess cholesterol lowering efficacy of these probiotic bacteria in humans.
Methods
Reagents. All chemicals were purchased from Sigma-Aldrich (Poole, UK) unless otherwise stated.
Studies in vitro. Lab4 was assessed for its ability to deconjugate bile salts, assimilate cholesterol and reg-
ulate Caco-2 cell cholesterol transport as previously described29. Overnight cultures of Lab4 grown in MRS 
broth (Oxoid, Hampshire, UK) were centrifuged (1,000 × g, 10 min), washed with phosphate buffered saline and 
re-suspended to 1 × 108 cfu/ml in antibiotic free Dulbecco’s Modified Eagle’s medium supplemented with 4.5 g/l 
glucose, 1% (v/v) non-essential amino acids and 10 mM HEPES.
Studies in vivo. Maintenance of animals and feeding of probiotics. Eighteen 8-week-old male C57BL/6 J 
mice were obtained from Harlan Laboratories (Oxfordshire, UK) and housed in pathogen-free scantainer venti-
lated cages (3 mice per cage) in a light- and temperature-controlled facility (lights on 7 a.m. −7 p.m., 22 °C). After 
one week acclimatisation on standard chow diet, 6 mice were sacrificed for baseline analysis and the remaining 12 
mice were randomly assigned into 2 groups; one group on high fat diet containing 21% (w/w) pork lard supple-
mented with 0.15% (w/w) cholesterol (Special Diets Services, Witham, U.K; product code: 821424) and the other 
on high fat diet supplemented with 5 × 108 cfu/mouse/day of Lab4 plus L. plantarum CUL66. The mice were fed 
10 g/cage/day (44.50 kcal/cage/day) for 14 days and cages were checked daily for surplus food. Body weights were 
recorded throughout the feeding period and faecal samples collected at the beginning and end of the study and 
were stored under anaerobic conditions at −80 °C for further analysis. At the end of the feeding period, all mice 
were terminally exsanguinated under anaesthesia by cardiac puncture and death confirmed by cervical disloca-
tion. All studies and protocols were approved by the Cardiff University institutional ethics review committee and 
the United Kingdom Home Office and experiments were performed in accordance with the Guide for the Care 
and Use of Laboratory Animals (NIH Publication No. 85–23, revised 1996).
Blood and tissue sampling. Blood obtained from cardiac puncture was collected into EDTA (10 mM final con-
centration) and the plasma separated by centrifugation (12,000 × g, 5 mins). Liver and intestinal tissue was snap 
frozen in liquid nitrogen. All samples were stored at −80 °C.
Plasma lipid and cytokine analysis. TC, HDL and TG concentrations were measured at the Clinical Biochemistry 
Service, Cardiff University, on an Aeroset automated analyzer (Abbott Diagnostics, Berkshire, UK). Plasma 
VLDL/LDL concentrations were measured using the VLDL/LDL cholesterol assay kit (ABCAM, Cambridge, 
UK) in accordance with the manufacturer’s instructions. Plasma cytokine concentrations were measured by the 
Central Biotechnology Service (Cardiff University, UK) using the VPLEX pro-inflammatory panel 1 mouse kit 
(Meso Scale Discovery, Maryland, USA).
UPLC-MS profiling of plasma and faecal bile acids. Plasma samples were prepared for analysis using a previ-
ously described method58. Faecal pellets were lyophilised for 48 hours using a VirTis Benchtop BTP 8ZL freeze 
dryer (BPS FUK). The dried pellets were weighed and then homogenised in a mixture of water, acetonitrile and 
2-propanol (2:1:1 vol.) using a Biospec bead beater with 1.0 mm Zirconia beads to extract bile acids. After centrifu-
gation (16,000 × g, 20 mins) the supernatant was passed through 0.45 μm microcentrifuge filters (Costar, Corning). 
Equal parts of the plasma and faecal filtrates were used for the preparation of quality control (QC) samples that are 
required to monitor the stability of the assay. QC samples were also spiked with mixtures of bile acid standards (55 
bile acid standards including 36 non-conjugated, 12 conjugated with taurine, 7 conjugated with glycine (Steraloids, 
Newport, RI)) to determine the chromatographic retention times of bile acids. The filtrate was transferred in LCMS 
vials and used for the subsequent analysis. Plasma and faecal bile acid analysis was performed by ACQUITY UPLC 
(Waters Ltd, Elstree, UK) coupled to a Xevo G2 Q-ToF mass spectrometer equipped with an electrospray ioni-
zation source operating in negative ion mode (ESI-), using the method described by Sarafian et al.58. Waters raw 
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data files were converted to NetCDF format and data were extracted via XCMS (v1.50) package with R (v3.1.1) 
software. MassLynx software 4.1 was used respectively for data acquisition and validation for this high throughput 
semi-targeted method for relative quantification of bile acids. Relative faecal bile acid intensities were corrected to 
the faecal pellet dry weight. PCA was carried out on the integrated mass spectrometric data using pareto scaling 
and logarithmic transformation using SIMCA v14.1.0.2047 (MKS Umetrics, Umeå, Sweden). The heatmaps were 
generated in R using package NMF using the scale command for the columns to create Z-scores.
Gene expression analysis. Approximately 50 mg of liver or intestinal scrapings were transferred into prefilled 
Lysis Matrix D micro-centrifuge tubes (MP Biomedicals, UK) containing 500 µl of Ribozol (Amresco LLC, Ohio, 
USA). The tissue was homogenized for 60 seconds at 6.0 m/s on a Fastprep-24TM homogenizer (MP Biomedicals, 
UK) and total RNA was isolated in accordance with the manufacturer’s instructions (Ribozol, Amresco LLC, 
Ohio, USA). Total RNA (1 µg) was reverse transcribed into cDNA using the High Capacity cDNA reverse tran-
scription Kit (Life Technologies, Paisley, UK) in accordance with the manufacturer’s instructions and real-time 
quantitative polymerase chain reaction (RT-qPCR) was performed on 10 ng cDNA using the iTag Universal 
SYBR Green SuperMix (Bio-Rad, Hertfordshire, UK) and 50 nM of each gene-specific oligonucleotide primer 
(See Supplementary Table S2): Initial melting (95 °C for 5 minutes) followed by 40 cycles of melting (94 °C for 
15 seconds), annealing (60 °C for 15 seconds) and extension (72 °C for 30 seconds) was performed using a CFX 
ConnectTM Real-Time Instrument (Bio-Rad). Transcript levels in the HFD + P group were determined using 
2−(ΔCt1–ΔCt2), where ΔCt represents the difference between the Ct for each target gene and β-Actin mRNA tran-
script levels and are expressed as a ratio of expression relative to the HFD group.
Statistical analysis. All data are presented as the mean ± standard deviation (SD) of the assigned number of 
independent experiments or number of mice. Prior to significance testing, the normality of the data and the equality of 
group variance were confirmed using the Shapiro-Wilk and Levene’s tests respectively. Where necessary, normality was 
achieved using logarithmic transformation. For single comparisons, values of p were determined using Student’s t-test. 
For multiple comparisons, values of p were determined using one-way analysis of variance (ANOVA) with Tukey’s 
(equal variance) or Dunnett’s T3 (unequal variance) post-hoc analysis. Statistical analysis was performed using SPSS 
statistical software package version 22 (IBM, New York, USA). Significance was defined when p < 0.05.
Data availability statement. The datasets generated during and/or analysed during the current study are 
available from the corresponding author on reasonable request.
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